Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-23T04:07:01.056Z Has data issue: false hasContentIssue false
  • English
  • Français

Expression of CD44 variant isoforms, CD44v3 and CD44v6, are associated with prognosis in nasopharyngeal carcinoma

Published online by Cambridge University Press:  25 July 2016

K Sagawa ,
N Uwa ,
T Daimon ,
M Sakagami  and
T Tsujimura
K Sagawa
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, Hyogo College of Medicine, Nishinomiya, Japan
N Uwa*
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, Hyogo College of Medicine, Nishinomiya, Japan
T Daimon
Affiliation:
Department of Biostatistics, Hyogo College of Medicine, Nishinomiya, Japan
M Sakagami
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, Hyogo College of Medicine, Nishinomiya, Japan
T Tsujimura
Affiliation:
Department of Pathology, Hyogo College of Medicine, Nishinomiya, Japan
*
Address for correspondence: Dr Nobuhiro Uwa, Department of Otorhinolaryngology – Head and Neck Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan Fax: +81 798 41 8976 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

The clinical and prognostic significance of CD44 variant isoform expression in nasopharyngeal carcinoma is not well known. This study aimed to clarify whether CD44 variant isoform expression serves as a prognostic factor in nasopharyngeal carcinoma.

Methods:

Forty-two nasopharyngeal carcinoma patients, who underwent concurrent chemoradiotherapy as the initial treatment, were the subjects of investigation. Expression of CD44 variant isoforms, CD44v3, CD44v4, CD44v5, CD44v6 and CD44v7, in nasopharyngeal carcinoma was assessed in relation to concurrent chemoradiotherapy resistance and disease-specific survival of the patients.

Results and conclusion:

The patients with CD44v6 high expression showed a clinically incomplete response to concurrent chemoradiotherapy at the primary site. The disease-specific survival rate was lower in patients with high expression of CD44v3 than in those with low expression. These results suggest that analysis of CD44v6 and CD44v3 expression is useful in estimating prognosis and determining effective treatment strategies in nasopharyngeal carcinoma.

Keywords

CD44 AntigensNasopharyngeal CarcinomaImmunohistochemistrySurvival RateChemoradiotherapy
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 130 , Issue 9 , September 2016 , pp. 843 - 849
Copyright
Copyright © JLO (1984) Limited 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Presented at the 117th Annual Meeting of the American Academy of Otolaryngology –Head and Neck Surgery, 29 September – 2 October 2013, Vancouver, Canada.

References

1 Kwong, DL, Sham, JS, Au, GK, Chua, DT, Kwong, PW, Cheng, AC et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004;22:2643–53CrossRefGoogle ScholarPubMed
2 Liu, MT, Hsieh, CY, Chang, TH, Lin, JP, Huang, CC, Wang, AY. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol 2003;33:50–8Google Scholar
3 Ponta, H, Sherman, I, Herrlich, PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33–45 Google Scholar
4 Goodison, S, Urquidi, V, Tarin, D. CD44 cell adhesion molecules. Mol Pathol 1999;52:189–96Google Scholar
5 Kalish, ED, Iida, N, Moffat, FL, Bourguignon, LY. A new CD44V3-containing isoform is involved in tumor cell growth and migration during human breast carcinoma progression. Front Biosci 1999;4:A1–8Google Scholar
6 Iida, N, Bourguignon, LY. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995;162:127–33Google Scholar
7 Ni, HM, Leong, AF, Cheong, D, Hooi, SC. Expression of CD44 variants in colorectal carcinoma quantified by real-time reverse transcriptase-polymerase chain reaction. J Lab Clin Med 2002;139:59–65 CrossRefGoogle ScholarPubMed
8 Kuhn, S, Koch, M, Nübel, T, Ladwein, M, Antolovic, D, Klingbeil, P et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007;5:553–67Google Scholar
9 Lee, SC, Harn, HJ, Lin, TS, Yeh, KT, Liu, YC, Tsai, CS et al. Prognostic significance of CD44v5 expression in human thymic epithelial neoplasms. Ann Thorac Surg 2003;76:213–18Google Scholar
10 Handorean, AM, Yang, K, Robbins, EW, Flaig, TW, Iczkowski, KA. Silibinin suppresses CD44 expression in prostate cancer cells. Am J Transl Res 2009;1:80–6Google ScholarPubMed
11 Wang, SJ, Wong, G, de Heer, AM, Xia, W, Bourguignon, LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009;119:1518–30Google Scholar
12 Kunishi, M, Kayada, Y, Yoshiga, K. Down-regulated expression of CD44 variant 6 in oral squamous cell carcinoma and its relationship to regional lymph node metastasis. Int J Oral Maxillofac Surg 1997;26:280–3Google Scholar
13 Tsuruoka, S, Matsuo, K, Ishikawa, A, Yamamoto, N, Yamashita, Y, Takahashi, T. Prognostic significance of CD44v3 and CD44v6 in oral squamous cell carcinoma of the tongue. Oral Med Pathol 2011;15:10–12 CrossRefGoogle Scholar
14 Uwa, N, Kataoka, TR, Torii, I, Sato, A, Nishigami, T, Song, M et al. CD44 expression is related to poor prognosis of hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2011;131:32–9CrossRefGoogle ScholarPubMed
15 R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing Google Scholar
16 Sobin, LH, Gospodarowicz, MK, Wittekind, C. TNM Classification of Malignant Tumours. Hoboken, NJ: Wiley-Blackwell, 2009 Google Scholar
17 Bourguignon, LY, Gilad, E, Brightman, A, Diedrich, F, Singleton, P. Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem 2006;281:14026–40Google Scholar
18 Wang, SJ, Bourguignon, LY. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132:771–8Google Scholar
19 Trachootham, D, Alexandre, J, Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579–91Google Scholar
20 Diehn, M, Cho, RW, Lobo, NA, Kalisky, T, Dorie, MJ, Kulp, AN et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780–3Google Scholar
21 Gottesman, MM, Fojo, T, Bates, SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58 Google Scholar
22 Prince, ME, Sivanandan, R, Kaczorowski, A, Wolf, GT, Kaplan, MJ, Dalerba, P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973–8CrossRefGoogle ScholarPubMed